芬兰1型糖尿病个体残余胰岛素分泌:纵向与横断面分析
该研究在芬兰1型糖尿病人群中分析随机血清C肽的影响因素及其与糖尿病并发症的关联。纵向分析纳入赫尔辛基大学医院新诊断患者847例<16岁和110例≥16岁,横断面分析纳入FinnDiane研究3984例和DIREVA研究645例。中位病程21.6年时19.4%的FinnDiane参与者有残余C肽分泌(>0.02 nmol/L),与较低1型糖尿病多基因风险相关(p<0.0001),并与肾病(调整OR 0.61,95%CI 0.38-0.96,p=0.033)和视网膜病变(0.55,0.34-0.89,p=0.014)呈独立负相关。
要点
- 纵向分析中诊断年龄与C肽分泌下降强烈相关。
- 中位病程21.6年时19.4%的FinnDiane参与者有残余随机血清C肽分泌(>0.02 nmol/L)。
- 残余C肽与较低1型糖尿病多基因风险相关(p<0.0001),且与肾病和视网膜病变独立负相关。
核心结论
- 尽管多重自身抗体和HLA风险基因型的儿童迅速进展至绝对胰岛素缺乏,许多青少年和成人诊断后数十年仍有残余随机血清C肽。
- 1型和2型糖尿病多基因风险影响残余随机血清C肽。
- 即使低浓度残余随机血清C肽似乎也与有利的并发症谱相关。
研究设计与样本
- 纵向分析纳入赫尔辛基大学医院(芬兰赫尔辛基)新诊断1型糖尿病患者,要求诊断3个月内及至少一次 later 有重复随机血清C肽和同步血糖测量,共847例<16岁和110例≥16岁。
- 长期横断面分析纳入芬兰57个中心的FinnDiane研究参与者(1型糖尿病诊断年龄>5岁、诊断1年内起始胰岛素治疗、C肽浓度<1.0 nmol/L)共3984例,以及DIREVA研究的1型糖尿病患者645例。
- 采用单因素方差分析检验随机血清C肽浓度和多基因风险评分的关联,采用逻辑回归检验随机血清C肽浓度、多基因风险评分和临床因素的关联。
主要发现
- 纵向分析中诊断年龄与C肽分泌下降强烈相关。
- 横断面分析中,中位病程21.6年(IQR 12.5-31.2)时,3984例FinnDiane参与者中776例(19.4%)有残余随机血清C肽分泌(>0.02 nmol/L),其1型糖尿病多基因风险低于无随机血清C肽者(p<0.0001)。
- 随机血清C肽与高血压、HbA1c和胆固醇呈负相关,但也与微血管并发症独立相关:肾病调整OR 0.61(95%CI 0.38-0.96),p=0.033;视网膜病变调整OR 0.55(95%CI 0.34-0.89),p=0.014。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contrary to the presumption that type 1 diabetes leads to an absolute insulin deficiency, many individuals with type 1 diabetes have circulating C-peptide years after the diagnosis. We studied factors affecting random serum C-peptide concentration in individuals with type 1 diabetes and the association with diabetic complications. METHODS: Our longitudinal analysis included individuals newly diagnosed with type 1 diabetes from Helsinki University Hospital (Helsinki, Finland) with repeated random serum C-peptide and concomitant glucose measurements from within 3 months of diagnosis and at least once later. The long-term cross-sectional analysis included data from participants from 57 centres in Finland who had type 1 diabetes diagnosed after 5 years of age, initiation of insulin treatment within 1 year from diagnosis, and a C-peptide concentration of less than 1·0 nmol/L (FinnDiane study) and patients with type 1 diabetes from the DIREVA study. We tested the association of random serum C-peptide concentrations and polygenic risk scores with one-way ANOVA, and association of random serum C-peptide concentrations, polygenic risk scores, and clinical factors with logistic regression. FINDINGS: The longitudinal analysis included 847 participants younger than 16 years and 110 aged 16 years or older. In the longitudinal analysis, age at diagnosis strongly correlated with the decline in C-peptide secretion. The cross-sectional analysis included 3984 participants from FinnDiane and 645 from DIREVA. In the cross-sectional analysis, at a median duration of 21·6 years (IQR 12·5-31·2), 776 (19·4%) of 3984 FinnDiane participants had residual random serum C-peptide secretion (>0·02 nmol/L), which was associated with lower type 1 diabetes polygenic risk compared with participants without random serum C-peptide (p<0·0001). Random serum C-peptide was inversely associated with hypertension, HbA1c, and cholesterol, but also independently with microvascular complications (adjusted OR 0·61 [95% CI 0·38-0·96], p=0·033, for nephropathy; 0·55 [0·34-0·89], p=0·014, for retinopathy). INTERPRETATION: Although children with multiple autoantibodies and HLA risk genotypes progressed to absolute insulin deficiency rapidly, many adolescents and adults had residual random serum C-peptide decades after the diagnosis. Polygenic risk of type 1 and type 2 diabetes affected residual random serum C-peptide. Even low residual random serum C-peptide concentrations seemed to be associated with a beneficial complications profile. FUNDING: Folkhälsan Research Foundation; Academy of Finland; University of Helsinki and Helsinki University Hospital; Medical Society of Finland; the Sigrid Juselius Foundation; the "Liv and Hälsa" Society; Novo Nordisk Foundation; and State Research Funding via the Helsinki University Hospital, the Vasa Hospital District, Turku University Hospital, Vasa Central Hospital, Jakobstadsnejdens Heart Foundation, and the Medical Foundation of Vaasa.
引用
- Harsunen M, Haukka J, Harjutsalo V, et al. Residual insulin secretion in individuals with type 1 diabetes in Finland: longitudinal and cross-sectional analyses. Lancet Diabetes Endocrinol. 2023. PMID: 37290465. doi:10.1016/S2213-8587(23)00123-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。